
Stay informed on the latest in arthritis prevention, research, treatment and care with JointHealth™ express, Canada's trusted source for arthritis news. Delivered right to your inbox, this "breaking news" bulletin provides timely updates on key arthritis topics, including disease management, research breakthroughs, and treatment advancements. As the longest-running arthritis news source in Canada, JointHealth™ express provides you expert insights from patients and analysis from arthritis health care professionals to help you on your arthritis journey. Stay connected to the arthritis information that matters most.
Click here to see JointHealth™ express bulletins from 2023 and earlier.
Latest News

Arthritis At Home 278 – Lupus updates and the Lupus International Congress

New blog post from Joint Journeys, life with arthritis by Carrie: Today is about the mountain

Call for patient input on tofacitinib for juvenile idiopathic arthritis
Canada’s Drug Agency (CDA-AMC) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s ...

Arthritis At Home 277 – ACE National Survey on Artificial Intelligence and Arthritis Care

ACE Launches National Survey on Artificial Intelligence and Arthritis Care

Arthritis At Home 276 – Determinants of health inequities and decision-making in juvenile idiopathic arthritis care

Arthritis At Home 275 – Moving more with inflammatory arthritis and strategies for behaviour change

Arthritis At Home 274 – Inflammatory bowel disease and its connection with spondyloarthritis

JointHealth™ insight – May 2025

New blog post from Joint Journeys, life with arthritis by Carrie: RA on the trail

Arthritis At Home 273 – Safety of rituximab, antinuclear antibody testing in lupus, and deprescribing

Update on availability of infliximab biosimilar Inflectra®
The infliximab biosimilar Inflectra® will be discontinued in Canada as of September 30, 2025. This means that patients currently receiving ...